This core will provide tissue culture and animal models for CHAIN investigators. The objectives of this core are to isolate and propagate primary human leukocytes (monocytes and peripheral blood lymphocytes and to provide rodent and primate models of CHAIN. Rigorous quality control measures are in place for this well integrated core. Primary human leukocytes will be fractionated into monocytes and lymphocytes from HIV-1, 2 and hepatitis B and C seronegative donors by centrifugal elutriation. Human glia (microglia and astrocytes) and/or neurons will be obtained from fetal tissues. The neurons and glia from human brain tissue will be purified, characterized and provided for experiments. These will provide data for common endpoints of disease. In toto, this 'cell, fissue, and animal core'will provide all the biological specimens necessary to address research objectives of the center research programs and utilize the carefully controlled specimens obtained through this infrastructure to invesfigate neural immunity and its links to CHAIN. The techniques in the Core as a whole will also support neuroimmunological studies relevant to microglial activation in CHAIN. The results obtained from this core will have direct applicability for determining the mechanisms and monitoring the course of HIV infection in its chronic stage. Our overriding goal is to assist CHAIN Pis and other researchers interested in neuroAIDS in determining and characterizing changes of CNS function as they develop in the various in vitro and in vivo models of neuroAIDS, and in exploring therapeutic potentials aiming at ameliorating or reversing such functional changes.
This core will provide tissue culture and animal models for the center investigators. The objecfives are to isolate and propagate primary human cells and to provide established animal models of chronic HIV infection and aging. This core will provide all the biological specimens necessary to address research objectives of the center activities to investigate neural immunity and its links to NeuroAIDS, and thus vital component for achieving our overriding goal: To explore therapeutic potentials aiming at ameliorafing or reversing such functional changes.
|Villeneuve, Lance M; Purnell, Phillip R; Stauch, Kelly L et al. (2016) HIV-1 transgenic rats display mitochondrial abnormalities consistent with abnormal energy generation and distribution. J Neurovirol :|
|Li, Weizhe; Tong, Hsin-I; Gorantla, Santhi et al. (2016) Neuropharmacologic Approaches to Restore the Brain's Microenvironment. J Neuroimmune Pharmacol 11:484-94|
|Singh, Dhirender; McMillan, JoEllyn; Hilaire, James et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) 11:1913-27|
|Sajja, Balasrinivasa R; Bade, Aditya N; Zhou, Biyun et al. (2016) Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2RÎ³c(null) Mouse Brain Atlas. J Neuroimmune Pharmacol 11:133-41|
|Jaeger, Philipp A; Lucin, Kurt M; Britschgi, Markus et al. (2016) Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener 11:31|
|Bade, Aditya N; Gorantla, Santhi; Dash, Prasanta K et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Mol Neurobiol 53:3286-97|
|Zhang, Gang; Guo, Dongwei; Dash, Prasanta K et al. (2016) The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12:109-22|
|Burns, Ariel; Ciborowski, Pawel (2016) Acute exposure to methamphetamine alters TLR9-mediated cytokine expression in human macrophage. Immunobiology 221:199-207|
|Yang, Lu; Yao, Honghong; Chen, Xufeng et al. (2016) Role of Sigma Receptor in Cocaine-Mediated Induction of Glial Fibrillary Acidic Protein: Implications for HAND. Mol Neurobiol 53:1329-42|
|Dong, Weiguo; Embury, Christine M; Lu, Yaman et al. (2016) The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-Î² degradation. J Neuroinflammation 13:184|
Showing the most recent 10 out of 337 publications